Summary
Study CP-MGC018-02 is a study of vobramitamab duocarmazine (MGC018) in combination with
lorigerlimab (MGD019). The study is designed to characterize safety, tolerability,
pharmacokinetics (PK), immunogenicity, pharmacodynamics, and preliminary antitumor
activity. Participants with relapsed or refractory, unresectable, locally advanced or
metastatic solid tumors including, but not limited to, metastatic castration-resistant
prostate cancer (mCRPC), melanoma, pancreatic cancer, hepatocellular carcinoma (HCC),
ovarian cancer, and renal cell carcinoma (RCC) will be enrolled.
Vobramitamab duocarmazine and lorigerlimab are administered separately on Day 1 of every
4-week (28-day) cycle at the assigned dose for each cohort. Participants who do not meet
criteria for study drug discontinuation may receive study drugs for up to 2 years.
Tumor assessments are performed every 8 weeks (± 7 days) for the initial 6 months on
study drugs, then every 12 weeks (± 21 days) until progressive disease (PD).
Participants will be followed for safety throughout the study. .